Nourmohammadi Hassan, Dehkordi Ali Hasanpour, Adibi Amir, Amin Hashemipour Seyed Mohammad, Abdan Mohsen, Fakhri Moloud, Abdan Zahra, Sarokhani Diana
Department of Internal Medicine, Shahid Mostafa Khomeini Hospital, Ilam, Iran.
Social Determinants of Health Research Center, School of Allied Medical Sciences, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Adv Virol. 2022 Jul 21;2022:9342680. doi: 10.1155/2022/9342680. eCollection 2022.
Determining the prevalence of SARS-CoV-2 in blood donors makes the control of virus circulation possible in healthy people and helps implement strategies to reduce virus transmission. The purpose of the study was to examine the seroprevalence of COVID-19 in blood donors using systematic review and meta-analysis.
The electronic databases PubMed, Scopus, Web of Science, and the Google Scholar search engine were searched using standard keywords up to 2022-04-26. The variance of each study was calculated according to the binomial distribution. Studies were combined according to the sample size and variance. Cochrane test and I2 index were used to examine the heterogeneity of the studies. Data analysis was performed in STATA 14 software, and the significance level of the tests was < 0.05.
In the 28 papers examined with 227894 samples, the seroprevalence of COVID-19 in blood donors was 10% (95% CI: 9%, 11%), estimated 5% (95% CI: 4%, 7%) among men and 6% (95% CI: 4%, 7%) among women. This rate in different blood groups was as follows: A 12% (95% CI: 10%-14%), B 12% (95% CI: 10%-15%), AB 9% (95% CI: 7%-12%), and O 13% (95% CI: 11%-16%). The seroprevalence of COVID-19 in blood donors in North America 10%, Europe 7%, Asia 23%, South America 5%, and Africa was 4%; Moreover, the seroprevalence of IgG antibodies was estimated to be 23% (95% CI: 18%-29%) and IgM 29% (95% CI: 9%-49%).
The highest prevalence of COVID-19 serum in women blood donors was among blood group O and Asia. The seroprevalence of IgG and IgM antibodies was high too.
确定献血者中SARS-CoV-2的流行率有助于控制病毒在健康人群中的传播，并有助于实施减少病毒传播的策略。本研究的目的是通过系统评价和荟萃分析来检测献血者中COVID-19的血清流行率。
使用标准关键词检索电子数据库PubMed、Scopus、Web of Science和谷歌学术搜索引擎，检索截至2022年4月26日的文献。根据二项分布计算每项研究的方差。根据样本量和方差对研究进行合并。采用Cochrane检验和I²指数检验研究的异质性。使用STATA 14软件进行数据分析，检验的显著性水平<0.05。
在纳入的28篇论文中，共227894个样本，献血者中COVID-19的血清流行率为10%（95%CI：9%，11%），男性估计为5%（95%CI：4%，7%），女性为6%（95%CI：4%，7%）。不同血型的这一比例如下：A型12%（95%CI：10%-14%），B型12%（95%CI：10%-15%），AB型9%（95%CI：7%-12%），O型13%（95%CI：11%-16%）。北美献血者中COVID-19的血清流行率为10%，欧洲为7%，亚洲为23%，南美为5%，非洲为4%；此外，IgG抗体的血清流行率估计为23%（95%CI：18%-29%），IgM为29%（95%CI：9%-49%）。
女性献血者中COVID-19血清流行率最高的是O型血和亚洲地区。IgG和IgM抗体的血清流行率也很高。
Zotero 插件
